



NEVADA STATE BOARD OF PHARMACY

985 Damonte Ranch Pkwy, Ste 206, Reno, NV 89521

(775) 850-1440 • 1-800-364-2081 • FAX (775) 850-1444

Email: pharmacy@pharmacy.nv.gov • Web Page: bop.nv.gov

BOARD MEETING MINUTES

April 15-16, 2026

The Nevada State Board of Pharmacy will conduct a meeting beginning Wednesday, April 15, 2026, at 9:00 am. The meeting will continue Thursday, April 16, 2026, at 9:00 am if necessary or until the Board concludes its business.

Pursuant to NRS 241.023(1)(c) the meeting is being conducted by means of remote technology. The public may attend the meeting via live stream remotely or at the following location:

Hyatt Place
1790 E Plumb Ln
Reno, NV

Via Videoconference at Zoom:

<https://zoom.us/j/5886256671> or

Via Teleconference at 1 (669) 900-6833

Meeting ID: 588 625 6671

Board Members Present:

Helen Park	Jade Jacobo	Adam Porath	Krystal Freitas
Richard Tomasso	Anna Carr		

Board Members Absent:

Chanyis Taylor

Board Staff Present:

David Wuest	Yenh Long	Gregory Zunino	Brett Kandt
Laura Tucker	Skylar Young	Todd Weiss	Darlene Nases
Erin Miller	Monica Segedy	Ryan Miller	Pat Comney
Mui Lee	William Kuykendall	Jesette Phaynarikone	

Call to Order and Roll Call – Establishment of Quorum

President Park performed the roll call. Board members were present, and a quorum was established.

Public Comment on April 15, 2026, 9:03 AM

There was no public comment.

3. Approval of March 4-5, 2026, Board Meeting Minutes (**FOR POSSIBLE ACTION**)

Board Action:

Motion: Jade Jacobo moved to approve the March 4-5, 2026, Board Meeting Minutes.

Second: Adam Porath

Action: Passed unanimously.

◆ CONSENT AGENDA ◆

The Consent Agenda contains matters of routine acceptance. The Board Members may approve the consent agenda items as written or, at their discretion, may address individual items for discussion or change.

4. 4.1 Applications for Out-of-State Medical, Devices, Equipment and Gases License (NAC 639.6944) – Non-Appearance (**FOR POSSIBLE ACTION**)

- A. Aeroflow Inc – Arden, NC
- B. Anodyne Inc – Minnetonka, MN
- C. Comfort Medical LLC – Tigard, OR
- D. HR HealthCare Patient Services – Woodstock, GA
- E. Ivy Technology LLC – Louisville, KY
- F. Livongo Health LLC – Lewisville, TX
- G. Orthofix US LLC – Lewisville, TX
- H. Pediatric Orthotic & Prosthetic Services – Sacramento, CA
- I. Reliable Respiratory Inc – Norwood, MA
- J. Shield California Health Care Center Inc – Valencia, CA
- K. Shield Denver Health Care Center Inc – Aurora, CO
- L. Urological Supplies Inc – Fort Myers, FL
- M. Watkins-Conti Products Inc – Edmond, OK

4.2 Applications for Out-of-State Wholesaler License (NRS 639.233) – Non-appearance (**FOR POSSIBLE ACTION**)

Background Check Not Required by Law.

- 4.2.1 Publicly Traded (NAC 639.593(6)(a))
 - N. McKesson Medical Surgical – Uxbridge, MA
- 4.2.2 Publicly Traded and VAWD-Accredited (NAC 639.593(6)(a) and (c))
- 4.2.3 Publicly Traded and Manufacturer (NAC 639.593(6)(a) and (d))
- 4.2.4 Publicly Traded, VAWD-Accredited, and Manufacturer (NAC 639.593(6)(a), (c), and (d))
- 4.2.5 VAWD-Accredited (NAC 639.593(6)(c))
 - O. Langham Logistics Inc – Whitestown, IN
 - P. Langham Logistics Inc – Whiteland, IN
 - Q. On Target Laboratories Inc – West Lafayette, IN
 - R. Patterson Veterinary Supply Inc – Saint Paul, MN
- 4.2.6 Manufacturer (NAC 639.593(6)(d))
 - S. AOSS Medical Supply LLC – Richardson, TX
 - T. Aryeh Pharma Corp – Skillman, NJ
 - U. Aurora Pharmaceutical Inc – Northfield, MN
 - V. Avadel CNS Pharmaceuticals LLC – Chesterfield, MO
 - W. Bayer Medical Care Inc – Indianola, PA
 - X. Bayer Medical Care Inc – Pittsburgh, PA
 - Y. Carl Zeiss Meditec USA Inc – Dublin, CA
 - Z. Genzyme Corporation – Cambridge, MA
 - AA. Safecor Health LLC – Rockford, IL
 - BB. Sanofi Vaccines US Inc – Swiftwater, PA
 - CC. Scioto Pharmaceuticals LLC – Columbus, OH
 - DD. Umedica Laboratories USA Inc – Parsippany, NJ
 - EE. Upsher-Smith Laboratories LLC – Maple Grove, MN
- 4.2.7 VAWD-Accredited and Manufacturer (NAC 639.593(6)(c) and (d))
 - FF. Clinical Solutions Wholesale LLC – Franklin, TN
- 4.2.8 Distributor for Single Manufacturer (NAC 639.593(6)(e))

- GG. EnableCV LLC – West Valley City, UT
- HH. Sequel Med Tech LLC – Manchester, NH

4.2.9 Background checks completed in compliance with NRS 639.500.

- II. Birdi Inc – Plymouth, MI
- JJ. Klutch Cargo LLC – Chicago, IL

**4.3 Application for Nevada Pharmacy License (NRS 639.230) – Non-Appearance
(FOR POSSIBLE ACTION)**

- KK. Renown Pharmacy – Reno, NV

**4.4 Applications for Out-of-State Compounding Pharmacy License (NRS 639.2328) –
Non-Appearance (FOR POSSIBLE ACTION)**

- LL. Accumix Pharmacy – Elmhurst, IL
- MM. Beaker Pharmacy – McKinney, TX
- NN. Blue Door Pharmacies LLC – Rockville, MD
- OO. Green Stone Rx – Miami, FL
- PP. InfuCare Rx – Glendale, CA
- QQ. InfuCare Rx – Kenner, LA
- RR. InfuCare Rx – Aston, PA
- SS. RxCompoundStore.Com – Miami, FL
- TT. St. Luke Compounding Pharmacy – New Port Ritchey, FL
- UU. Tailor Made Compounding – Nicholasville, KY
- VV. University Compounding Pharmacy – San Diego, CA

**4.5 Applications for Out-of-State Pharmacy License (NRS 639.2328) – Non-
Appearance (FOR POSSIBLE ACTION)**

- WW. AnovoRx Group LLC – Chandler, AZ
- XX. AnovoRx Group LLC – Memphis, TN
- YY. ClearMedix Pharmacy LLC – Worthington, OH
- ZZ. Customedico Pharmacy + Wellness – Scottsdale, AZ
- AAA. Infinite Health Pharmacy Inc – West Palm Beach, FL
- BBB. Medbridge Pharmacy – Granada Hills, CA
- CCC. MRH Outpatient Pharmacy – Aberdeen, MS
- DDD. Specialty Care Rx – Orange, CA
- EEE. Spectrum Solutions Rx LLC – Draper, UT
- FFF. Swyft Scripts – DFW – Hurst, TX

- 4.6 Application for Nevada Ambulatory Surgery Center License (NAC 639.4992) – Non-Appeal (FOR POSSIBLE ACTION)

GGG. Desert Rose Surgery Center – Las Vegas, NV

- 4.7 Request to Engage in The Practice of Pharmacy at a Site Other Than a Licensed Pharmacy – Non-Appeal (FOR POSSIBLE ACTION)

HHH. Ivan Fernandez

- 4.8 Recommended Denial of Registration/Licensure Due to Material Omissions on Application – Non-Appeal (FOR POSSIBLE ACTION)

- 4.9 Application for Out-of-State Outsourcing Facility (NRS 639.100) – Non-Appeal (FOR POSSIBLE ACTION)

III. Hyalo Technologies LLC – Somerset, NJ

8. Applications for Nevada Pharmacy License (NRS 639.230) – Appearance (FOR POSSIBLE ACTION)

A. Carson Valley Health – Gardnerville, NV

David Wuest, Executive Secretary for the Nevada Board of Pharmacy, stated that Agenda Item 8A would be added to the Consent Agenda.

Board discussion ensued.

Adam Porath recused himself from Agenda Items 4KK and 8A of the Consent Agenda.

Board Action:

Motion: Jade Jacobo moved to approve Consent Agenda Items 4KK and 8A.

Second: Richard Tomasso

Action: Motion passed (Porath recused).

Board Action:

Motion: Jade Jacobo moved to approve the Consent Agenda with the exception to Agenda Items 4KK and 8A.

Second: Anna Carr

Action: Passed unanimously.

◆ REGULAR AGENDA ◆

5. Disciplinary hearings pursuant to NRS 639.247. **(FOR POSSIBLE ACTION)**

- | | |
|--------------------|----------------|
| C. Renown Pharmacy | (25-139-PH-N) |
| D. Oliver Swafford | (25-139-RPH-N) |

Adam Porath recused himself from this matter due to his employment.

Marie Ellerton, Esq. (counsel for Renown), Israa Mahmood (Pharmacy Director for Renown), Bill Stilling, Esq. (counsel for Oliver Swafford), and Oliver Swafford were present.

Brett Kandt, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Renown Pharmacy, alleging that, as pharmacy/pharmacy owner, Renown Pharmacy is responsible for the acts of its employees who made an error in a prescription that resulted in a negative outcome to the patient.

The proposed stipulated penalties for Renown Pharmacy, Pharmacy License No. PH04283, are the following: 1) Respondent fined \$10,000 for the violations; and 2) Respondent assessed \$1,000 in attorney's fees and costs, both to be due and payable by June 1, 2026.

Mr. Kandt prosecuted the case against Oliver Swafford alleging that Respondent Swafford made an error in a prescription that resulted in a negative outcome to the patient.

The proposed stipulated penalties for Oliver Swafford, Certificate of Registration No. 17452, are the following: 1) Respondent's Certificate of Registration No. 17452 is placed on probation for a period of one (1) year from the effective date of the Order; 2) Respondent fined \$2,000 for the violations; and 3) Respondent assessed \$500 in attorney's fees and costs, both to be due and payable by June 1, 2026.

Board discussion ensued.

Board Action:

Motion: Jade Jacobo moved to approve the Stipulation and Orders for Renown Pharmacy and Oliver Swafford as presented by Mr. Kandt.

Second: Anna Carr

Action: Motion passed (Porath recused).

Lyn Beggs, Esq., was present on behalf of Martin Farrell.

Brett Kandt, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Martin Farrell alleging that Respondent Farrell was disciplined by the Pennsylvania Board of Pharmacy for submitting altered endotoxin and sterility test certificates for equine glucosamine injections and for misrepresenting acceptable levels to FDA inspectors. The Nevada Board of Pharmacy imposed reciprocal discipline.

The proposed stipulated penalties for Martin Farrell, Certificate of Registration No. 22316, are the following: 1) Respondent's Certificate of Registration No. 22316 is placed on probation for a period of one (1) year from the effective date of the Order; and 2) Respondent fined \$1,000 for the violations.

Board discussion ensued.

Board Action:

Motion: Adam Porath moved to approve the Stipulation and Order for Martin Farrell as presented by Mr. Kandt.

Second: Jade Jacobo

Action: Passed unanimously.

F. CVS Pharmacy #8792

(25-247-PH-N)

G. Joshua Lee

(25-247-RPH-N)

Jade Jacobo recused herself from this matter.

Brian Convery, Esq. (Representative for CVS Pharmacy #8792) and Joshua Lee were present.

Brett Kandt, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against CVS Pharmacy #8792, alleging that, as pharmacy/pharmacy owner, CVS Pharmacy #8792 is responsible for the acts of its employees who made an error in a prescription.

Mr. Kandt, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Joshua Lee alleging that as the supervising pharmacist, Respondent Lee is responsible for the acts of an intern pharmacist who made an error in a prescription.

The proposed stipulated penalties for CVS Pharmacy #8792, Pharmacy License No. PH00637 are the following: 1) Respondent fined \$2,000 for the violations; 2)

Respondent assessed \$1,000 in attorney's fees and costs, both to be due and payable by June 1, 2026.

The proposed stipulated penalties for Joshua Lee, Certificate of Registration No. 24163 are the following: 1) Respondent fined \$1,000 for the violations; 2) Respondent assessed \$500 in attorney's fees and costs, both to be due and payable by June 1, 2026.

Board discussion ensued.

Board Action:

Motion: Adam Porath moved to approve the Stipulation and Orders for CVS Pharmacy #8972 and Joshua Lee as presented by Mr. Kandt.

Second: Anna Carr

Action: Motion passed (Jacobco recused).

- U. CVS Pharmacy #9586 (25-350-PH-N)
- V. Mark Pardini (25-350-RPH-N)

Jade Jacobo recused herself from this matter due to her prior employment.

Brian Convery, Esq. (Representative for CVS Pharmacy #9586) and Mark Pardini were present.

Laura Tucker, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against CVS Pharmacy #9586, alleging that, as pharmacy/pharmacy owner, CVS #9586 is responsible for the act of a pharmacist who made an error in a prescription.

Ms. Tucker, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Mark Pardini alleging that Respondent Pardini made an error in a prescription.

The proposed stipulated penalties for CVS Pharmacy #9586, Pharmacy License No. PH01821, are the following: 1) Respondent fined \$1,000 for the violations; 2) Respondent assessed \$500 in attorney's fees and costs, both to be due and payable within thirty (30) days of this order.

The proposed stipulated penalties for Mark Pardini, Certificate of Registration No. 08849, are the following: 1) Respondent fined \$1,000 for the violations; 2) Respondent assessed \$500 in attorney's fees and costs, both to be due and payable within thirty (30) days of this order.

Board discussion ensued.

Board Action:

Motion: Richard Tomasso moved to approve the Stipulation and Order for Mark Pardini as presented by Ms. Tucker.

Second: Adam Porath

Action: Motion passed (Jacobco recused).

The proposed amended stipulated penalties for CVS Pharmacy #9586, Pharmacy License No. PH01821, are the following: 1) Respondent fined \$5,000 for the violations; 2) Respondent assessed \$500 in attorney's fees and costs, both to be due and payable within thirty (30) days of this order.

Board discussion ensued.

Board Action:

Motion: Richard Tomasso moved to approve the amended Stipulation and Order for CVS Pharmacy #9586.

Second: Anna Carr

Action: Motion passed (Jacobco recused).

I. Patrick Awa

(24-366-RPH-N)

Patrick Awa was present.

Gregory Zunino, Senior General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Patrick Awa alleging that Respondent Awa failed to document whether counseling was offered or provided for a dispensed prescription as required by state regulation.

The proposed stipulated penalties for Patrick Awa, Certificate of Registration No. 20399, are the following: 1) Respondent fined \$750 for the violations; 2) Respondent assessed \$500 in attorney's fees and costs; and 3) Respondent shall complete two (2) additional continuing education hours on pharmacy record keeping and provide proof to the Board by May 31, 2026.

Board discussion ensued.

Board Action:

Motion: Adam Porath moved to approve the Stipulation and Order for Patrick Awa as presented by Mr. Zunino.

Second: Jade Jacobo

Action: Passed unanimously.

Q. Michael Stellmacher

(24-364-CS-S)

Anthony Cortez, Esq. (counsel), and Michael Stellmacher were present.

Laura Tucker, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Michael Stellmacher alleging that during Respondent Stellmacher's tenure as Premier Beauty's medical director, he rarely visited the spa while dangerous drugs were stored, ordered, and administered. Employees injected prescription medications without the medical director present, without a bona fide therapeutic relationship, and for whom Respondent had neither diagnosed nor determined that a dangerous drug was medically necessary. Additionally, the spa also obtained drugs from an unlicensed Florida wholesaler and kept multiple injectable products intended for foreign markets and not approved for distribution or use in the United States.

The proposed stipulated penalties for Michael Stellmacher, Certificate of Registration No. CS21884, are the following: 1) Respondent fined \$2,500 for the violations; 2) Respondent assessed \$1,000 in attorney's fees and costs, both to be due and payable by June 30, 2026.

Board discussion ensued.

The proposed amended stipulated penalties for Michael Stellmacher, Certificate of Registration No. CS21884, are the following: 1) Respondent fined \$5,000 for the violations; 2) Respondent assessed \$1,000 in attorney's fees and costs; and 3) Respondent Stellmacher cannot serve as medical director of any practice site in the State of Nevada where injectable dangerous drugs and controlled substances are in the possession of individuals who do not hold a license to possess them in Nevada for a period of five (5) years from the effective date of the Order.

Board discussion ensued.

Board Action:

Motion: President Park moved to approve the amended Stipulation and Order for Michael Stellmacher as presented by Ms. Tucker.

Second: Jade Jacobo

Action: Passed unanimously.

Lyn Beggs, Esq., was present on behalf of Sean Arora.

Gregory Zunino, Senior General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Sean Arora alleging that Respondent Arora was the medical director of Youth, Inc. During this period, the owner and/or employees stored and possessed prescription drugs and administered injectable prescription drugs at times when no practitioner was on-site.

The proposed stipulated penalties for Sean Arora, Certificate of Registration No. CS31476, are the following: 1) Respondent accepts this Stipulation as a public reprimand for having assisted or permitted the unauthorized storage, possession and administration of drugs; 2) Respondent fined \$5,000 for the violations; and 3) Respondent assessed \$500 in attorney's fees and costs, both to be due and payable by May 31, 2026.

Board discussion ensued.

Board Action:

Motion: Adam Porath moved to approve the Stipulation and Order for Sean Arora as presented by Mr. Zunino.

Second: Anna Carr

Action: Passed unanimously.

Lyn Beggs, Esq., was present on behalf of Philip Rich.

Laura Tucker, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Philip Rich alleging that Respondent Rich did not check the PMP database for a patient's controlled-substance history or review the patient's utilization report before issuing a prescription. He also failed to review his own prescriber activity in the PMP system for the period between August 21, 2023, and August 12, 2025.

The proposed stipulated penalties for Philip Rich, Certificate of Registration No. CS02308, are the following: 1) Respondent agrees to participate in training with Board staff on use of the PMP system within sixty (60) days of the effective date of this Order; 2) Respondent fined \$5,000 for the violations; and 3) Respondent assessed \$1,000 in attorney's fees and costs, both to be due and payable within sixty (60) days of this Order.

Board discussion ensued.

Board Action:

Motion: Krystal Freitas moved to approve the Stipulation and Order for Philip Rich as presented by Ms. Tucker.

Second: Adam Porath

Action: Passed unanimously.

S. Laura Oki

(25-112-CS-A-N)

Craig Perry, Esq., was present on behalf of Laura Oki.

Laura Tucker, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Laura Oki alleging that Respondent Oki was medical director of Skin Lab from April 23, 2023, to February 18, 2024, again from December 18, 2024, to May 31, 2025, and from June 1, 2025, to the present. During this time, Respondent allowed all employees unrestricted access to the facility's dangerous drug inventory and failed to maintain the security of the dangerous drugs within her possession.

The proposed stipulated penalties for Laura Oki, Certificate of Registration No. CS24180, are the following: 1) Respondent fined \$5,000 for the violations; and 2) Respondent assessed \$500 in attorney's fees and costs, both to be due and payable within six (6) months of this Order.

The proposed amended stipulated penalties for Laura Oki, Certificate of Registration No. CS24180, are the following: 1) Respondent fined \$5,000 for the violations; 2) Respondent assessed \$500 in attorney's fees and costs, both to be due and payable within six (6) months of this Order; and 3) Respondent Oki cannot serve as medical director of any practice site in the State of Nevada where injectable dangerous drugs and controlled substances are in the possession of individuals who do not hold a license to possess them in Nevada for a period of five (5) years from the effective date of the Order.

Board discussion ensued.

Board Action:

Motion: President Park moved to approve the amended Stipulation and Order for Laura Oki as presented by Ms. Tucker.

Second: Anna Carr

Action: Passed unanimously.

Jay DeVoy, Esq., was present on behalf of Apria Healthcare LLC.

Laura Tucker, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Apria Healthcare LLC alleging that Apria Healthcare, a licensed medical products provider, received a CPAP prescription for a patient in June 2024 but did not deliver the device until July 2025, despite billing the patient’s insurer for its use from August to October 2024 and for additional supplies in 2025. The delay stemmed from an error in Respondent’s system. Apria Healthcare’s actions fell below Nevada’s professional and billing standards, and Apria Healthcare also failed to document patient communications, respond timely to Board inquiries, and maintain required records.

Both parties stipulated to dismiss Count Three and Count Four in the accusation.

The proposed stipulated penalties for Apria Healthcare LLC, License No. MP00030, are the following: 1) Respondent fined \$3,000 for the violations; and 2) Respondent assessed \$1,000 in attorney’s fees and costs, both to be due and payable within thirty (30) days of this Order.

Board discussion ensued.

Board Action:

Motion: Jade Jacobo moved to approve the Stipulation and Order for Apria Healthcare LLC as presented by Ms. Tucker.

Second: Adam Porath

Action: Passed unanimously.

- W. Lyfe Pharmacy (25-360-PH-S)
- X. Nazokat Nigmatova (25-360-RPH-S)
- Y. Tera Pharmacy (25-370-PH-S)
- Z. Nazokat Nigmatova (25-370-RPH-A-S)

George Koury, Esq. (Counsel), was present on behalf of Lyfe Pharmacy, Tera Pharmacy, and Nazokat Nigmatova.

President Park disclosed that she was familiar with Nazokat Nigmatova but could participate in this matter fairly and without bias.

Laura Tucker, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Lyfe Pharmacy alleging that the pharmacy owner, Nazokat Nigmatova, caused the assets of Lyfe Pharmacy to be sold to Ramy Massoud on September 26, 2024, without providing the required advance notice to the Board or filing a

change-of-ownership application, as mandated by Nevada Law. As a result, Mr. Massoud operated the pharmacy without a valid license, continuing to handle and dispense dangerous drugs and controlled substances unlawfully. Lyfe Pharmacy is responsible for the acts of its employees who enabled unlicensed pharmacy operations.

Ms. Tucker, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Tera Pharmacy alleging that the pharmacy owner, Nazokat Nigmatova, sold its assets to Mark Mahfouz on September 19, 2025, without providing the required advance notice to the Board or filing a change-of-ownership application, as mandated by Nevada Law. Also, a pharmacist processed at least ten prescriptions lacking information required under Nevada law. Tera Pharmacy is responsible for the acts of its employees who enabled unlicensed pharmacy operations and processed ten prescriptions without the required information required by Nevada Law.

Ms. Tucker, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Nazokat Nigmatova alleging that as pharmacy owner, Respondent Nigmatova, sold the pharmacy assets for Lyfe Pharmacy to Ramy Massoud on September 26, 2024, and the pharmacy assets for Tera Pharmacy to Mark Mahfouz on September 19, 2025, without providing the required advance notice to the Board or filing a change-of-ownership application, as mandated by Nevada Law.

The pharmacy licenses for Tera Pharmacy and Lyfe Pharmacy have been placed on inactive status.

The proposed stipulated penalties for Nazokat Nigmatova, Certificate of Registration No. 20601, are the following: Respondent's Certificate of Registration No. 20601 is suspended for a period of two (2) years. The suspension is stayed and Respondent is placed on probation, subject to the following conditions: 1) Respondent fined \$5,000 for the violations; 2) Respondent assessed \$2,000 in attorney's fees and costs, both to be due and payable within six (6) months of the date of this Order; 3) as a condition of probation, Respondent Nigmatova shall not engage in any conduct for which disciplinary action may be imposed; and 4) Respondent may not own a pharmacy in Nevada for a period of three (3) years from the effective date of this Order, and Respondent shall seek Board approval for any ownership of a pharmacy after the prohibition of ownership has ended.

Board discussion ensued.

Board Action:

Motion: Richard Tomasso moved to approve the Stipulation and Order for Nazokat Nigmatova, Lyfe Pharmacy, and Tera Pharmacy as presented by Ms. Tucker.

Second: Adam Porath

Action: Passed unanimously.

H. Raymond Graber

(23-340-CS-N)

No one was present on behalf of Raymond Graber.

Gregory Zunino, Senior General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Raymond Graber alleging that Respondent Graber was disciplined by the Nevada Board of Pharmacy on October 11, 2023, and placed on five (5) years of probation with a requirement to complete substance-abuse counseling and provide proof of progress. He failed to renew his certificate of registration on November 1, 2024, and thereafter failed to provide proof of continuing participation in substance-abuse counseling.

Mr. Zunino called Darlene Nases as a witness.

Darlene Nases, Board Coordinator, answered questions and gave testimony.

Mr. Zunino requested that the Board make a Finding of Fact that Respondent Graber did not satisfy the terms and conditions of his probation, and to revoke his Certificate of Registration No. CS27126 retroactively to October 31, 2024.

Board discussion ensued.

Board Action:

Motion: President Park moved to find that Board staff properly noticed the Respondent of the charges and this hearing in conformance with Nevada law.

Second: Jade Jacobo

Action: Passed unanimously.

Board Action:

Motion: Jade Jacobo moved to make the Findings of Fact that Respondent Graber did not comply with the terms and conditions of his probation.

Second: Adam Porath

Action: Passed unanimously.

Board Action:

Motion: Jade Jacobo moved to retroactively revoke Respondent Graber's

Certificate of Registration No. CS27126 to October 31, 2024.

Second: Adam Porath

Action: Passed unanimously.

Board Action:

Motion: Jade Jacobo moved to not allow Respondent Graber to petition for reinstatement for a period of one (1) year from the effective date of the Order.

Second: President Park

Action: Passed unanimously.

- A. Festus Ebonka (19-012-CS-S)
- B. Festus Ebonka (25-215-CS-S)

Liborius Agwara, Esq. (counsel), and Festus Ebonka were present.

Brett Kandt, General Counsel for the Nevada Board of Pharmacy, prosecuted the cases against Festus Ebonka; 25-215-CS-S alleging that Respondent Ebonka was convicted of a federal crime for the unlawful conversion of Medicare funds for personal use, and was also appearing on an order to show cause alleging that respondent had failed to comply with the Board's order in 19-012-CS-S.

Mr. Kandt amended the charging document in 25-215-CS-S on the record to reflect the exact language used in the criminal conviction, noted that the paragraphs were misnumbered and that Respondent's Certificate of Registration No. CS23430 was currently suspended pursuant to NRS 639.2107, and gave an opening statement.

Mr. Agwara gave his opening argument; stated that Mr. Ebonka was now compliant with the Board order in 19-012-CS-S, as he paid the past due attorney's fees and costs assessed.

Mr. Kandt gave no closing argument.

Mr. Agwara gave his closing argument.

Board discussion ensued.

Board Action:

Motion: Jade Jacobo moved to deny the Order to Show Cause for Case No. 19-012-CS-S.

Second: Richard Tomasso

Action: Passed unanimously.

Mr. Kandt requested the Board make Findings of Fact consistent with the factual allegations in the Accusation as amended in 25-215-CS-S.

Board Action:

Motion: Jade Jacobo moved to make Findings of Fact consistent with the factual allegations in the Accusation as amended in 25-215-CS-S.

Second: Anna Carr

Action: Passed unanimously.

Mr. Kandt requested the Board to make Conclusions of Law consistent with paragraphs 3-7 of the Accusation in 25-215-CS-S and to find respondent guilty on Counts One through Four as set forth in the Accusation as amended.

Board Action:

Motion: Jade Jacobo moved to make Conclusions of Law consistent with paragraphs 3-7 of the Accusation in 25-215-CS-S and to find respondent guilty on Counts One through Four as set forth in the Accusation as amended.

Second: Anna Carr

Action: Passed unanimously.

Mr. Kandt submitted a Memorandum of Attorney's Fees and Costs in the amount of \$670.37 to be entered into the record and assessed against Respondent.

Mr. Agwara had no objection to the Memorandum of Attorney's Fees and Costs.

President Park admitted the Memorandum of Attorney's Fees and Costs as Exhibit 1.

Board discussion ensued.

Board Action:

Motion: President Park moved that Respondent Ebonka's Certificate of Registration No. CS23430 remain suspended until October 31, 2026.

Second: Jade Jacobo

Action: Passed unanimously.

N. Gezel Ashley Gonzalez

(26-092-PTT-N)

Adam Porath recused himself from this matter due to his employment with Renown Pharmacy.

Gezel Ashley Gonzalez was present.

Brett Kandt, General Counsel for the Nevada Board of Pharmacy, prosecuted the case against Gezel Gonzalez alleging that Respondent Gonzalez provided false information on her Pharmaceutical Technician-in-Training application by claiming she had obtained a high school diploma or GED, despite never having completed or received either credential.

Ms. Gonzalez requested to submit her proof of high school equivalency test and professional reference letters as exhibits.

Mr. Kandt had no objection to the exhibits being entered.

President Park admitted Ms. Gonzalez' proof of equivalency test and professional reference letters as Exhibit 1.

Yenh Long, Deputy Secretary for the Nevada Board of Pharmacy, requested the Board to allow Board staff to process a new application submitted by Ms. Gonzalez without her needing to reappear in front of the Board on the application, and to accept the 1,500 hours that Ms. Gonzalez acquired during her time when she was practicing as a pharmaceutical technician-in-training.

Ms. Gonzalez gave no closing statement.

Mr. Kandt requested the Board to make Findings of Fact consistent with paragraphs 1-3 of the Accusation.

Board Action:

Motion: Jade Jacobo moved to make Findings of Fact consistent with paragraphs 1-3 of the Accusation.

Second: President Park

Action: Motion passed (Porath recused).

Mr. Kandt requested the Board to make Conclusions of Law consistent with paragraphs 4-10 of the Accusation and to find the respondent guilty on Counts One and Two.

Board Action:

Motion: Jade Jacobo moved to make Conclusions of Law consistent with paragraphs 4-10 of the Accusation and to find the respondent guilty on Counts One and Two.

Second: Anna Carr

Action: Motion passed (Porath recused).

Mr. Kandt submitted a Memorandum of Attorney's Fees and Costs in the amount of \$586.34 to be entered into the record and assessed against Respondent.

President Park admitted Memorandum of Attorney's Costs and Fees into evidence as Exhibit 2.

Mr. Kandt requested that the Board cancel Ms. Gonzalez' Certificate of Registration No. PT28532 pursuant to NRS 639.281, fine Respondent \$500 for the violations, and assess Respondent \$586.34 in attorney's fees and costs, effective immediately.

Board Action:

Motion: Jade Jacobo moved to cancel Certificate of Registration No. PT28532; no fine; and Respondent assessed \$586.34 in attorney's fees and costs as reasonable, necessary and actually incurred, both to be due and payable within six (6) months of the date of this Order, effective immediately.

Second: Anna Carr

Action: Motion passed (Porath recused).

I. Raley's Pharmacy #123 (24-366-PH-N)

This matter was continued.

K. PharMerica (24-370-PH-N)

This matter was continued.

L. Camilla Kim (24-370-RPH-N)

This matter was continued.

M. Cassie Gifford (24-509-PR-A-N)

This matter was continued.

N. Gabrielle McIntyre (24-509-PR-B-N)

This matter was continued.

O. Allison Jaggard (24-509-PR-C-N)

This matter was continued.

6. Appeal hearing pursuant to NRS 639.2895(2) **(FOR POSSIBLE ACTION)**

A. Oxus America, Inc (25-470-O)

This matter was continued.

7. Applications for Nevada Medical, Devices, Equipment and Gases License (NAC 639.6944) – Appearance **(FOR POSSIBLE ACTION)**

B. Montgomery DME – Las Vegas, NV

Jay Devoy (counsel), Ramiro Velazquez (Facility Manager), Tom Fisher (CEO and President), and Yolanda Greene (consultant) were present.

The Board heard testimony and asked questions of the applicant.

Board discussion ensued.

Board Action:

Motion: Adam Porath moved to approve the Nevada Medical, Devices, Equipment and Gases registration for Montgomery DME, pending a favorable inspection, with the addition of quarterly inspections by Board staff at the owner's expense, and that the Board receives GenuCare's inspection reports, updated policies and procedures, and updated respiratory therapist training plan.

Second: Jade Jacobo

Action: Passed unanimously.

8. Applications for Nevada Pharmacy License (NRS 639.230) – Appearance **(FOR POSSIBLE ACTION)**

B. LUX Infusion 13 – Henderson, NV

Bill Stilling, Esq. (counsel), Jonathan Chan (Managing Pharmacist), Morgan Harber (Chief Administrative Officer and General Counsel), Allison Croft (Vice President of Compliance and Quality), Kim Moore (Senior Vice President of Pharmacy Operations), and Robyn Hansen (Regulatory Compliance Consultant) were present.

The Board heard testimony and asked questions of the applicant.

Joe Dodge, Board inspector, gave insight on his previous inspection.

Board discussion ensued.

Board Action:

Motion: Dick Tomasso moved to approve the Nevada Pharmacy License for LUX Infusion 13, pending a favorable inspection.

Second: Jade Jacobo

Action: Passed unanimously.

13. Applications for Controlled Substance Registration (NRS 453.226) – Appearance
(FOR POSSIBLE ACTION)

A. Frances Anne Puesta

Lyn Beggs, Esq. (counsel), and Frances Anne Puesta were present.

The Board heard testimony and asked questions of the applicant.

Board discussion ensued.

Board Action:

Motion: Anna Carr moved to approve the controlled substance registration for Frances Anne Puesta.

Second: Adam Porath

Action: Passed unanimously.

8. Applications for Nevada Pharmacy License (NRS 639.230) – Appearance **(FOR POSSIBLE ACTION)**

E. Specialty Care Rx – Las Vegas, NV

Blanca Monterroza, Director of Contracts and Regulatory Affairs, was present.

The Board heard testimony and asked questions of the applicant.

Board discussion ensued.

Board Action:

Motion: Jade Jacobo moved to approve the Nevada Pharmacy registration for Specialty Care Rx.

Second: Adam Porath

Action: Passed unanimously.

7. Applications for Nevada Medical, Devices, Equipment and Gases License (NAC 639.6944) – Appearance (**FOR POSSIBLE ACTION**)

A. Dignified Medical Equipment LLC – Las Vegas, NV

Maan Simon (Owner and Manager) and Yordanys Diaz (Administrative Assistant) were present.

The Board heard testimony and asked questions of the applicant.

Board discussion ensued.

Board Action:

Motion: President Park moved to approve the Nevada Medical, Devices, Equipment and Gases registration for Dignified Medical Equipment LLC, with the amendment to only include assistive equipment and incontinence supplies as their products offered, and pending a favorable inspection.

Second: Jade Jacobo

Action: Passed unanimously.

C. Sora Health LLC – Las Vegas, NV

Mimi Deng, CEO and founder, was present.

The Board heard testimony and asked questions of the applicant.

Board discussion ensued.

Board Action:

Motion: Jade Jacobo moved to approve the Nevada Medical, Devices, Equipment and Gases registration for Sora Health LLC.

Second: Anna Carr

Action: Passed unanimously.

13. Applications for Controlled Substance Registration (NRS 453.226) – Appearance
(FOR POSSIBLE ACTION)

B. Jeffrey Gross

Jeffrey Gross was present.

The Board heard testimony and asked questions of the applicant.

Board discussion ensued.

Board Action:

Motion: Adam Porath moved to approve the controlled substance registration for Jeffrey Gross, to match the stipulations of the DEA memorandum.

Second: Jade Jacobo

Action: Passed unanimously.

Public comment at April 15, 2026, at 5:01 PM:

Mark Brennan, public member.

Emily Smith, public member.

Kelly Turner, Practitioner.

President Park recessed the meeting for the night and reconvened the meeting the next morning at 9:00 AM.

Board Members Present:

Helen Park

Jade Jacobo

Adam Porath

Krystal Freitas

Richard Tomasso

Anna Carr

Board Members Absent:

Chanyis Taylor

Board Staff Present:

David Wuest	Yenh Long	Gregory Zunino	Brett Kandt
Laura Tucker	Skylar Young	Todd Weiss	Darlene Nases
Erin Miller	Dena McClish	Darla Zarley	Jessette Phaynarikone
John Castaldo	Ken Scheuber	Clayton Bailey	William Kuykendall
Michael Castaneda			

Call to Order and Roll Call – Establishment of Quorum

President Park performed the roll call. All Board members were present, and a quorum was established.

Public comment at April 16, 2026, at 9:05 AM:

There was no public comment.

◆ WORKSHOP ◆

Thursday, April 16, 2026 – 9:00 am

15. Notice of Proposed Regulation Workshop Pursuant to NRS 233B.061(2) **(FOR POSSIBLE ACTION):**

- B. Amendment to Nevada Administrative Code (NAC) 453. The proposed amendments relate to controlled substances adding mitragynine, 7-hydroxymitragynine and mitragynine pseudoindoxyl to the controlled substances listed in Schedule I.

David Wuest, Executive Secretary for the Nevada Board of Pharmacy, presented the proposed regulation workshop to the Board.

Shayla Holmes, representative from the Nevada Substance Use Response Working Group (SURG) which was established in 2021 through Assembly Bill 374 to develop and recommend strategies for preventing, treating, and responding to substance misuse and disorders in Nevada, gave background on the recommendation given to the Board of Pharmacy.

Darla Zarley, Grant and Project Analyst for Nevada Board of Pharmacy, presented background information regarding the proposed regulation workshop to the Board.

Laura Knight, Chief Medical Examiner and Coroner for the Washoe County Regional Medical Examiner's Office, gave background on Kratom fatalities in Northern NV.

President Park opened the floor for public comment.

The following person(s) offered public comment in opposition:

Martin Beimer, public member.

Andrew Sarrels, public member.

Dr. Jack Henningfield, public member.

Tony Vargas, public member.

Adriana Vargas, public member.

Sinjen Smith, public member and GreenVibe World nonprofit organizer.

Mac Haddow, public member.

Dr. Michele Ross, Addiction Neuroscientist.

Creighton McCain, public member.

The following person(s) offered public comment in support:

Lea Cartwright, public member.

Hilary Tesluck, Executive Director for End Kratom Addiction and public member.

Dan Gibbs, public member.

Matthew Winterhawk, public member.

Wendy Chamberlain, public member.

Susan Cave, public member.

Jade Jacobo left the meeting at 10:13 AM.

Jade Jacobo returned to the meeting at 10:15 AM.

Dick Tomasso left the meeting at 10:15 AM.

Dick Tomasso returned to the meeting at 10:17 AM.

DeNae Jones, public member.

Susan Eppard, public member.

President Park closed the period for public comment.

Board discussion ensued.

Board Action:

Motion: Jade Jacobo moved to approve the proposed regulation as presented by Board staff, and to have Board staff capture any of the known Kratom derivatives.

Second: Adam Porath

Action: Passed unanimously.

- A. Amendment to Nevada Administrative Code (NAC) 639. The proposed amendments establishes record keeping requirements of controlled substances by a pharmacy and other matters properly relating thereto.

Yenh Long, Deputy Secretary for the Nevada Board of Pharmacy, presented the proposed regulation workshop to the Board.

President Park opened the floor for public comment.

The following person(s) offered public comment:

Liz McMnamin, Retail Association of Nevada.

President Park closed the floor to public comment.

Board discussion ensued.

This item was tabled to be re-agendized to a future board meeting.

- C. Amendment to Nevada Administrative Code (NAC) 639.708. Regulation authorizing the delivery of a commercially manufactured prescription drug product to a practitioner.

David Wuest, Executive Secretary for the Nevada Board of Pharmacy, presented the proposed regulation workshop to the Board.

President Park opened the floor for public comment.

The following person(s) offered public comment:

Rob Geddes, Executive Director of Pharmacy Advocacy and Regulatory Affairs for CVS Pharmacy.

Laura Watkins, Professional Practices Leader for Walgreens Pharmacy.

Liz McMenamin, Retail Association of Nevada.

Board discussion ensued.

Board Action:

Motion: Adam Porath moved to approve the proposed regulation as presented by Board staff, with the amendment to remove “other than controlled substances” in Section 1 Sub A; for Board staff to address the time frame that a practitioner can hold onto a prescription medication delivered to the practitioner to 90 days; and for a practitioner to be able to assist in delivering the prescription from the pharmacy to the patient for a patient enrolled and receiving the prescription through a patient assistant program.

Second: Jade Jacobo

Action: Passed unanimously.

17. General Counsel Report

Gregory Zunino, Senior General Counsel for the Nevada Board of Pharmacy, and Brett Kandt, General Counsel for the Nevada Board of Pharmacy, presented.

18. Executive Secretary Report

David Wuest, Executive Secretary for the Nevada Board of Pharmacy, presented.

◆ PUBLIC HEARING ◆

Thursday, April 16, 2026 – 9:00 am

16. Notice of Proposed Regulation Public Hearing Pursuant to NRS 233B.061(2)
(FOR POSSIBLE ACTION)

- A. A REGULATION relating to the authority of a homeopathic physician who is not licensed as an allopathic or osteopathic physician in Nevada to possess, administer, prescribe and dispense controlled substances and dangerous drugs; and providing other matters properly relating thereto. (LCB File No. R106-25)

Brett Kandt, General Counsel for the Nevada Board of Pharmacy, presented the proposed regulation to the Board.

President Park opened the floor for public comment.

The following person(s) offered public comment:

Michael Gerber, public member.

Mary Linde, public member.

Renée Burch, public member.

Michael Gerber made another public comment.

Board discussion ensued.

Board Action:

Motion: Dick Tomasso moved to adopt LCB File No. R106-25 as presented by Board staff.

Second: Jade Jacobo

Action: Passed unanimously.

- B. Amendment to Chapter 639 of the Nevada Administrative Code. The proposed amendments reduce the minimum age to register to become a pharmaceutical technician in training along with modify certain requirements to become a pharmaceutical technician in training. (LCB FILE NO. R010-26)

David Wuest, Executive Secretary for the Nevada Board of Pharmacy, presented the proposed regulation workshop to the Board.

President Park opened the floor for public comment.

The following person(s) offered public comment:

Liz McMenamin, Retail Association of Nevada.

Board discussion ensued.

Board Action:

Motion: Jade Jacobo moved to adopt LCB File No. R010-26 as presented by Board staff.

Second: Anna Carr

Action: Passed unanimously.

11. Application for Pharmacist Registration by Reciprocity NRS 639.134) – Appearance (**FOR POSSIBLE ACTION**)

A. Mark Mullins

Mark Mullins was present.

The Board heard testimony and asked questions of the applicant.

Board discussion ensued.

Board Action:

Motion: Jade Jacobo moved to approve the pharmacist registration for Mark Mullins.

Second: Adam Porath

Action: Passed unanimously.

13. Applications for Controlled Substance Registration (NRS 453.226) – Appearance (**FOR POSSIBLE ACTION**)

C. Kelly Turner

Kelly Turner was present.

The Board heard testimony and asked questions of the applicant.

Board discussion ensued.

Board Action:

Motion: Jade Jacobo moved to approve the controlled substance registration for Kelly Turner.

Second: Adam Porath

Action: Passed unanimously.

14. Discussion and possible action to amend, revise and/or approve proposed FY27 budget (**FOR POSSIBLE ACTION**)

David Wuest, Executive Secretary for the Nevada Board of Pharmacy, presented.

Board discussion ensued.

Board Action:

Motion: Anna Carr moved to approve the proposed FY27 budget as presented by Board staff.

Second: Jade Jacobo

Action: Passed unanimously.

7. Applications for Nevada Medical, Devices, Equipment and Gases License (NAC 639.6944) – Appearance (**FOR POSSIBLE ACTION**)

- D. Supercare Health – Las Vegas, NV
- E. Supercare Health – Sparks, NV

Susean Nichols, Compliance Officer, was present.

The Board heard testimony and asked questions of the applicant.

Board discussion ensued.

Board Action:

Motion: Jade Jacobo moved to approve the Nevada Medical, Devices, Equipment and Gases registration for Supercare Health in Las Vegas, NV and Sparks, NV.

Second: Adam Porath

Action: Passed unanimously.

Jade Jacobo and Dick Tomasso left the meeting at 2:08 PM.

8. Applications for Nevada Pharmacy License (NRS 639.230) – Appearance **(FOR POSSIBLE ACTION)**

B. Las Vegas Apothecary – Las Vegas, NV

Andrew Roth, Owner and Designated Representative, was present.

President Park and Krystal Freitas disclosed that they are familiar with Andrew Roth and Desiree Roth, but could participate fairly in this matter and without bias.

The Board heard testimony and asked questions of the applicant.

Board discussion ensued.

Board Action:

Motion: Adam Porath moved to approve the pharmacy license for Las Vegas Apothecary.

Second: Anna Carr

Action: Passed unanimously.

10. Application for Nevada Wholesaler License (NRS 639.233) – Appearance – **(FOR POSSIBLE ACTION)**

A. Elizbiz Limited Liability Company – Henderson, NV - Background Check completed in compliance with NRS 639.500

Elizabeth Gichanga, Owner, was present.

The Board heard testimony and asked questions of the applicant.

Board discussion ensued.

President Park asked Ms. Gichanga if she would like to table her application.

This application was tabled.

8. Applications for Nevada Pharmacy License (NRS 639.230) – Appearance **(FOR POSSIBLE ACTION)**

D. Saint Mary Pharmacy – Las Vegas, NV

This matter was continued.

9. Application for Out-of-State Compounding Pharmacy License (NRS 639.2328) – Appearance – **(FOR POSSIBLE ACTION)**

- A. Med Solutions Compounding Pharmacy – Winston Salem, NC

This application was withdrawn.

12. Application for Pharmaceutical Technician in Training Registration (NAC 639.240) – Appearance. **(FOR POSSIBLE ACTION)**

- A. Camila Gonzalez

This application was withdrawn.

20. Public Comment:

President Park opened the floor for public comment.

There was no public comment.

President Park closed the floor for public comment.

19. Date and Location of Next Scheduled Board Meeting:

June 3-4, 2026 – Las Vegas, NV

21. Adjournment